NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.
We help you plan and evaluate strategies to achieve success in U.S. and global markets.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.
The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.
NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.
NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.
NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.
NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.
NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.
The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.
650+
+99%
<24
4,000+
24x7
99.5%
Join us at NAVLIN’s Pharma Pricing Innovation Conference (PPIC), which will take place on June 3-5 at the Movenpick in Basel, SwitzerlandJoin a cohort of peers and industry executives at the event’s 2025 incarnation, hosted by NAVLIN by EVERSANAConference registration includes access to pre-conference workshops, the two-day conference, exclusive networking events, and dinners. After the event, copies of all presentations will be available to attendees
The Argentine government is setting up a new National Agency for the Evaluation of Health Technology Financing, under the name ANEFiTS. The independent body will be tasked with conducting assessments of new medicines, assessing the clinical benefits of treatments and absorbing the responsibilities of the National Commission for the Assessment of Health Technologies and Clinical Excellence (CONETEC) and the Technical Assistance Council for Health Judicial Processes (CATPROS)Uniquely, submitting to ANEFiTS will be the first step before submitting to the National Administration of Drugs, Food, and Medical Technology (ANMAT), meaning that HTA will now precede regulatory approval in Argentina However, there are concerns that ANEFiTS may prevent or delay access. The Argentine Chamber of Medical Specialties (CAEMe) supports ANEFiTS but warns against it acting as a barrier to pharmaceutical innovation. There are also lingering questions over the yet-to-be chosen decision-makers at ANEFiTS and potential bottlenecks in the process. Meanwhile, the Institute for Clinical and Healthcare Effectiveness urged ANEFiTS to have a "high level of legitimacy"
A new coalition between the Christian Democratic Union (CDU), Christian Social Union (CSU) and Social Democrats (SPD) is emerging in Germany, and the group have released a working plan for healthcare, including a review of the controversial AMNOG "guardrails"The guardrails have been a massively unpopular addition to Germany’s pricing and reimbursement landscape in recent yearsWhile the document does not say much more, the passage reads: "We are developing AMNOG further with a view to the “guard rails” and personalized medicine. We enable access to innovative therapies and medicines and at the same time provide we ensure sustainable financing." The group also touches on relocalization, noting "We strengthen security of supply through relocation from production sites for critical pharmaceuticals and medical devices to Germany and Europe."
The UK government revealed plans to significantly raise the payment rates under the Statutory Scheme for Branded Medicines Pricing, requiring pharmaceutical companies to return a record-high percentage of NHS sales revenue. In response, the UK’s pharmaceutical industry has issued a stark warning to the government, stating that excessive medicine levies are driving investment away and threatening the country’s ambitions of becoming a global leader in life sciencesThe Japanese Ministry of Health, Labor and Welfare (MHLW) has unveiled new National Health Insurance (NHI) prices for the upcoming FY2025 drug price revisionUnder the joint Health Economics Methods Advisory (HEMA) initiative, the Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) announced that they will conduct an assessment of the benefits of treatment that are appropriate to consider in Health Technology Assessment (HTA) decision-making
The European Commission recently hosted a webinar for health technology developers (HTDs) of medicinal products, featuring insights from the Chairs and Co-chairs of the Member State Coordination Group on Health Technology Assessment (HTACG) and its subgroupsAnne Willemsen, Co-Chair of the Joint Clinical Assessments (JCA) Subgroup announced that under the new Health Technology Assessment Regulation (HTAR), two JCAs have already started, focusing on new cancer treatments and advanced therapy medicinal products (ATMPs)The first Joint Scientific Consultations (JSC) request period saw low demand, giving HTDs a good chance of selection. The HTA secretariat will notify applicants of the outcome within 15 working days, with the final selection deadline on March 24, 2025
We are pleased to announce that NAVLIN Daily is an official media partner with the World Vaccine Congress USA, taking place April 21-24, 2025, in Washington, DCThe event brings together global leaders, scientists, and industry experts across the entire vaccine landscape and offers a unique opportunity to explore cutting-edge developments, forge partnerships, and drive progress in vaccine innovationAs a valued NAVLIN customer, you can use our ND50 registration discount code for an exclusive 50% discount
We are pleased to announce that NAVLIN Daily is an official media partner with the World Orphan Drug Congress (WODC) USA, taking place April 22-24, 2025, at the Boston Convention and Exhibition Center in Boston, MassachusettsThe event convenes leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapiesAs a valued NAVLIN customer, you can use our NAVLIN50 registration discount code for an exclusive 50% discount
The Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) announced that they will conduct an assessment of the benefits of treatment that are appropriate to consider in Health Technology Assessment (HTA) decision-makingThe project is the first research topic coming out of the joint Health Economics Methods Advisory (HEMA) initiative established by the three HTA bodies in February 2025HEMA anticipates publishing a final report in December 2025
Eli Lilly has launched Mounjaro (tirzepatide) in India, beating out its key weight-loss market rival Novo Nordisk, which has yet to launch Wegovy (semaglutide) in India The once-weekly injection has been priced at USD 50.67 for a 5 mg vial and USD 40.54 for a 2.5 mg vial, aiming to help patients with type 2 diabetes and obesityNovo Nordisk is planning a 2026 launch, pending regulatory approvals and supply readiness. However, the report states that Novo's India executives have proposed advancing the release to 2025
Speaking at Advanced Therapies UK, Joshi Venugopal, General Manager and Head of Europe, at Novartis Gene Therapies suggested that gene therapy is emerging from its "trough of disillusionment" phase, and will likely take 10-15 years to reach widespread productivityVenugopal highlighted three key factors for successful gene therapy: improvements in diagnostics, technological breakthroughs, and commercialization strategies. He emphasized the importance of newborn genomic screening, while acknowledging variances in this throughout EuropeHe pointed to broader access strategies in Europe, like Novartis' approach with Zolgensma (onasemnogene abeparvovec), as a potential solution. While partnering with Big Pharma is one direction, Venugopal noted that it’s not a one-size-fits-all answer and supported the idea of large-scale, global commercial champions for rare diseases
